Connected With Latham
By Latham & Watkins
In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.
Latest episode
-
Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Conference. In this episode of Connected With Latham, Washington, D.C. partners and and associate ... -
Episode 93 – EU’s Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
The deadline for the EU's Digital Operational Resilience Act (DORA) has arrived. This regulation applies to most financial entities operating in the EU market and impacts a broad range of third-party providers of technology-related services. In this.… -
Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends
In this episode of Connected with Latham, the final of three episodes complementing Latham’s “10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025” report, London partners and and counsel discuss the key cross-sector... -
Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets
In this episode of Connected with Latham, the second of three episodes complementing Latham’s “10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025” report, London partners and and counsel discuss the upcoming reform agenda... -
Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets
In this episode of Connected with Latham, the first of three episodes complementing Latham’s “10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025” report, London partners and and counsel discuss what will likely appear on the... -
Episode 89 – The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What’s Next?
In this episode of Connected With Latham, , Global Vice Chair of Latham’s Emerging Companies & Growth Practice, sits down with ’s Co-Founder and Chief Executive Officer Neil Kumar and Chief Financial Officer Brian Stephenson. Since 2015,... -
Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
FDA enforcement activities range from administrative actions like conducting establishment inspections and issuing warning letters to judicial enforcement through the Department of Justice, which can take the shape of civil or criminal actions. While… -
Episode 87 – Drug Pricing: What’s In the New CMS Medicaid Final Rule?
The Centers for Medicare & Medicaid Services (CMS) recently published its final rule to implement the Medicaid Services Investment and Accountability Act of 2019 (MSIAA). The final rule significantly deviates from the agency’s 2023 proposal,... -
Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Manufacturers, government officials, and other stakeholders recently convened in Chicago for the annual Medicaid Drug Rebate Program Summit. In this episode of Connected with Latham, Washington, D.C. associate interviews partner about takeaways... -
Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
Recent Supreme Court decisions, such as the opinions in Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce that overruled the long-standing Chevron doctrine, will likely impact how federal agencies interpret ambiguous...
